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Background:  Definition of Performance Measures (PM) is a difficult task. We assessed the rate of use of, and the temporal changes in various PM 
in patients with ST segment elevation MI (STEMI) in Europe to determine the degree of application and areas with potential for improvement.
Methods:  The Euro Heart Survey Acute Coronary Syndromes-III (EHS-ACSIII) recruited patients with acute coronary syndromes from 138 centers 
and 21 countries from 2006 to 2008. The Steering Committee defined 9 PM for reperfusion, 7 PM for acute management and 6 PM at discharge. The 
degree of application was defined as the proportion of eligible patients, and room for improvement as a rate of use < 90%.
Results:  Among 19205 patients included in the registry, 8854 had STEMI; 84.7% were eligible for reperfusion, 38% had a LVEF<0.40 and 
92.9% were discharged. The rate of patients eligible for reperfusion remained stable, but the changes in primary PCI, thrombolytics and patients 
reperfused in a timely manner were significant. Among PM for acute management, the rates of use of aspirin and betablockers were stable, while 
use of clopidogrel and ACE inhibitors increased to exceed 95%. Conversely, adequate use of loading dose of clopidogrel according to the reperfusion 
strategy increased up to70%, leaving room for improvement. At discharge, the rates of use of aspirin, ACE inhibitors and beta-blockers were stable, 
while use of clopidogrel and statins increased to >95%. A combination of betablockers, ACE inhibitors and aldosterone antagonist was used in 40% 
of eligible patients (with heart failure and ejection fraction<0.40).
Conclusions:  Among the 22 PM defined by the EHS ACS III Steering Committee, times to reperfusion are applicable in 80% and improvable, 
clopidogrel use and loading dose according to the type of reperfusion is applicable in 100% of patients and improvable, PM for patients with 
LVEF<0.40 are applicable in 35% of the patients and improvable. Conversely, the use of aspirin, betablockers and statins at admission and 
discharge as PM is questionable since they have reached a plateau or do not leave room for improvement.
